Evidence and support

Brexanolone listings need an availability correction

FDA withdrew Zulresso approval effective April 14, 2025 after the sponsor reported it was no longer marketed.

Research preview · selected sources rechecked September 14, 2026 · independent clinical review pending. These editorial assessments are not formal GRADE ratings. No study here establishes an effect of Brighter Postpartum.

supported availability · C26

Brexanolone listings need an availability correction

Population and setting: US regulatory status.
What was found: FDA withdrew Zulresso approval effective April 14, 2025 after the sponsor reported it was no longer marketed.
Limits and applicability: Historical trials remain evidence but should not be presented as a routine currently marketed US option.

Sources: S39 · Evidence record ↗

Interpretation boundary

Prevention, treatment, comfort, mechanism and research status are separate questions. Read the original source and retain its population, timing and limitations. This is not a personalized recommendation or a claim that our support program has this effect.

Version 1. Independent clinical review pending. Explore the connected evidence.